Our principal, Ms. Pauli Wong, was invited by HKUST to speak at their Entrepreneurship 101 Training Program on the topic of protecting start-ups through intellectual property. Her talk, titled “Patent 101 for Entrepreneurs and Start-Ups,” covered the fundamentals of IP, with a particular focus on patents. She highlighted often-overlooked aspects and shared invaluable tips to help start-up entrepreneurs avoid common pitfalls.

Pauli really enjoyed giving the talk and felt inspired by the positive feedback from the audience. She found it rewarding to share her knowledge about intellectual property and its importance for entrepreneurs. This experience has motivated her to give more presentations in the future, as she wants to reach more people and help them understand IP better.

On a side note, we want to wish the HKUST Entrepreneurship Center a happy 25th anniversary, which they are celebrating this week!




Our Past Events

Recommended Insights

2020 China Top 10 IP Cases: Winners’ Sun is truly a Winner: A Simple Selfie-Stick Utility Model Patent Crushes Infringers in China

2 August 2021
Each year The Intellectual Property Tribunal of the Supreme People’s Court releases a list of top 10 technical intellectual property rights court case decisions. The 2020 list came out a few months ago, and we have been highlighting some of these cases. Today, we will cover a utility model patent infringement case. As one of […]

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

21 November 2019
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

4 January 2023
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]
Top crossarrow-right